GO:0050435 amyloid-beta metabolic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050435 (amyloid-beta metabolic process) describes all chemical reactions and pathways involving amyloid-beta and its precursor protein APP.
• The amyloid cascade hypothesis posits that accumulation of amyloid-beta peptides, especially oligomers, is an early driver of Alzheimer's disease pathogenesis.
• Soluble amyloid-beta oligomers share a common structure and are considered the most toxic species, impairing synaptic function.
• APP is sequentially cleaved by beta-secretase (BACE1) and gamma-secretase to generate amyloid-beta peptides of varying lengths, primarily Abeta40 and Abeta42.
• Dysregulation of metal ions such as copper and zinc influences amyloid-beta aggregation and toxicity.
• CRISPR-based models (knockout, knock-in, point mutation) enable precise dissection of genes in the amyloid-beta metabolic process for drug discovery.
Description
The amyloid-beta metabolic process (GO:0050435) encompasses the biochemical reactions and pathways that produce, modify, and clear amyloid-beta peptides, as well as the processing of its precursor, amyloid precursor protein (APP). This process is central to Alzheimer's disease (AD) research because the accumulation of amyloid-beta, particularly soluble oligomers, is widely considered an early and causative event in AD pathogenesis. The amyloid cascade hypothesis proposes that an imbalance between production and clearance of amyloid-beta leads to synaptic dysfunction, neuronal loss, and dementia. Given the high prevalence of AD and the lack of disease-modifying therapies, understanding the molecular details of amyloid-beta metabolism is a major focus of biomedical research. This article provides a comprehensive overview of the amyloid-beta metabolic process, its key genes, regulatory mechanisms, disease relevance, and the experimental models and methods used to study it, with a focus on CRISPR-based approaches.
amyloid-beta metabolic process At A Glance
| GO ID | GO:0050435 |
|---|---|
| GO term | amyloid-beta metabolic process |
| Ontology | biological_process |
| Synonym | amyloid-beta metabolism; beta-amyloid metabolic process; beta-amyloid metabolism |
| Major function | Production, modification, aggregation, and clearance of amyloid-beta peptides and APP processing |
| Related diseases | Alzheimer's disease, cerebral amyloid angiopathy |
| Key enzymes | BACE1, PSEN1, PSEN2, NCSTN, APH1A, APH1B, PEN2 |
| Key substrates | APP, amyloid-beta peptides (Abeta40, Abeta42) |
| Cellular locations | Plasma membrane, endosomes, Golgi apparatus, extracellular space |
What Is GO:0050435?
According to the Gene Ontology, amyloid-beta metabolic process (GO:0050435) is defined as the chemical reactions and pathways involving amyloid-beta, a glycoprotein associated with Alzheimer's disease, and its precursor, amyloid precursor protein (APP). This includes the proteolytic cleavage of APP by beta- and gamma-secretases to generate amyloid-beta peptides, post-translational modifications, aggregation, and clearance mechanisms. The term is a biological process and is synonymous with amyloid-beta metabolism, beta-amyloid metabolic process, and beta-amyloid metabolism.
Why Is amyloid-beta metabolic process Important in Cell Biology?
The amyloid-beta metabolic process is critically important because its dysregulation is a hallmark of Alzheimer's disease, the most common cause of dementia worldwide. The amyloid cascade hypothesis, supported by genetic and biochemical evidence, places amyloid-beta accumulation upstream of tau pathology, neuroinflammation, and neurodegeneration. Soluble amyloid-beta oligomers have been shown to impair synaptic plasticity and memory, and their levels correlate with cognitive decline. Moreover, mutations in APP and presenilin genes that alter amyloid-beta production cause early-onset familial AD, underscoring the causal role of this pathway. Therefore, targeting amyloid-beta metabolism remains a major therapeutic strategy, and understanding its molecular players is essential for developing effective interventions.
• Central to Alzheimer's disease pathogenesis and the amyloid cascade hypothesis.
• Amyloid-beta oligomers are synaptotoxic and correlate with cognitive deficits.
• Mutations in APP and presenilin genes cause early-onset familial Alzheimer's disease.
• Metal ions like copper and zinc modulate amyloid-beta aggregation and toxicity.
• The pathway is a prime target for disease-modifying therapies, including secretase inhibitors and immunotherapies.
• Understanding clearance mechanisms may reveal new therapeutic avenues.
• Amyloid-beta metabolism intersects with other neurodegenerative processes, such as tau hyperphosphorylation.
• Biomarkers of amyloid-beta (e.g., CSF Abeta42, PET imaging) are used for diagnosis and clinical trials.
• CRISPR screens can identify novel regulators of amyloid-beta production and toxicity.
• Modeling amyloid-beta metabolism in cells and animals is essential for preclinical drug testing.
What Happens During amyloid-beta metabolic process?
APP Processing and Amyloid-beta Generation
In simple terms: APP is cut by enzymes to release amyloid-beta peptides.
Amyloid precursor protein (APP) is a transmembrane protein that undergoes sequential proteolytic cleavage. In the amyloidogenic pathway, beta-secretase (BACE1) cleaves APP at the beta-site, generating a soluble APPbeta fragment and a membrane-bound C99 fragment. C99 is then cleaved by the gamma-secretase complex (presenilin, nicastrin, APH-1, PEN-2) within the transmembrane domain, releasing amyloid-beta peptides of varying lengths, predominantly Abeta40 and Abeta42. Abeta42 is more hydrophobic and aggregation-prone, and its relative increase is linked to familial AD mutations in APP and presenilins.
Amyloid-beta Aggregation and Oligomer Formation
In simple terms: Amyloid-beta peptides stick together to form toxic clumps.
Monomeric amyloid-beta can self-associate into oligomers, protofibrils, and mature fibrils. Soluble oligomers, rather than fibrils, are considered the primary toxic species; they share a common structure and induce synaptic dysfunction. Aggregation is influenced by peptide concentration, metal ions (copper, zinc, iron), and lipid environment. Oligomers can disrupt membrane integrity, impair long-term potentiation, and trigger neuroinflammation.
Amyloid-beta Clearance and Degradation
In simple terms: The body removes amyloid-beta through various clearance mechanisms.
Amyloid-beta is cleared from the brain by multiple mechanisms, including enzymatic degradation (e.g., neprilysin, insulin-degrading enzyme), receptor-mediated transport across the blood-brain barrier (e.g., LRP1, RAGE), and microglial phagocytosis. Impaired clearance, as seen in aging and APOE4 carriers, leads to amyloid-beta accumulation and plaque formation. The balance between production and clearance is critical for maintaining healthy brain function.
Metal Ion Interactions and Oxidative Stress
In simple terms: Metals like copper and zinc can affect amyloid-beta clumping and toxicity.
Amyloid-beta binds copper and zinc with high affinity, and these interactions modulate aggregation and reactive oxygen species production. Copper-bound amyloid-beta can catalyze Fenton chemistry, generating oxidative stress that contributes to neuronal damage. Zinc has been shown to induce amyloid-beta aggregation and is enriched in plaques. Targeting metal-amyloid-beta interactions is a potential therapeutic strategy.
Amyloid-beta and Synaptic Function
In simple terms: Amyloid-beta can disrupt communication between neurons.
Soluble amyloid-beta oligomers impair synaptic plasticity by interfering with NMDA and AMPA receptor trafficking, activating calcineurin, and promoting long-term depression. They also disrupt calcium homeostasis and mitochondrial function, leading to synaptic loss. These effects are thought to underlie early cognitive deficits in Alzheimer's disease.
Key Genes Involved in GO:0050435 amyloid-beta metabolic process
The following genes and proteins are key players in the amyloid-beta metabolic process, from APP processing to clearance and toxicity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APP | Amyloid precursor protein; substrate for beta- and gamma-secretases | Mutations cause familial AD; central to amyloid-beta production |
| BACE1 | Beta-secretase; cleaves APP to generate C99 | Therapeutic target; knockout reduces amyloid-beta |
| PSEN1 | Catalytic subunit of gamma-secretase; cleaves C99 | Mutations cause early-onset familial AD |
| PSEN2 | Gamma-secretase subunit; homolog of PSEN1 | Mutations linked to familial AD |
| NCSTN | Nicastrin; gamma-secretase complex component | Required for gamma-secretase activity |
| APH1A | Gamma-secretase subunit | Modulates enzyme activity and substrate specificity |
| APH1B | Gamma-secretase subunit | Alternative subunit with distinct roles |
| PEN2 | Gamma-secretase subunit | Essential for complex assembly and stability |
| APOE | Lipid transport; major genetic risk factor for late-onset AD | Influences amyloid-beta clearance and aggregation |
| LRP1 | Receptor for amyloid-beta clearance across BBB | Mediates transport and degradation |
| RAGE | Receptor for advanced glycation endproducts; binds amyloid-beta | Mediates amyloid-beta influx and neuroinflammation |
| IDE | Insulin-degrading enzyme; degrades amyloid-beta | Clearance enzyme; reduced in AD |
| MME | Neprilysin; major amyloid-beta degrading enzyme | Clearance; potential therapeutic target |
| CLU | Clusterin; chaperone involved in amyloid-beta clearance | Risk gene for AD; modulates aggregation |
| CR1 | Complement receptor 1; involved in clearance | Risk gene for AD; immune-mediated clearance |
| PICALM | Phosphatidylinositol binding clathrin assembly protein | Risk gene; affects APP trafficking |
| BIN1 | Bridging integrator 1; involved in endocytosis | Risk gene; modulates tau and amyloid-beta |
How Is amyloid-beta metabolic process Regulated?
The amyloid-beta metabolic process is tightly regulated at multiple levels. Transcriptional regulation of APP and secretases, alternative splicing of APP, and post-translational modifications influence amyloid-beta production. The gamma-secretase complex activity is regulated by subunit composition and interacting proteins. Clearance mechanisms are modulated by apolipoprotein E (APOE) isoforms, with APOE4 impairing amyloid-beta clearance and promoting aggregation. Additionally, metal ions such as copper and zinc regulate amyloid-beta aggregation and toxicity. Inflammatory pathways and microglial activation also affect amyloid-beta clearance and deposition. Dysregulation of these regulatory mechanisms contributes to amyloid-beta accumulation in Alzheimer's disease.
amyloid-beta metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APP | Familial Alzheimer's disease, cerebral amyloid angiopathy | Knock-in mice with Swedish mutation (KM670/671NL) |
| PSEN1 | Early-onset familial Alzheimer's disease | Knock-in mice with PSEN1 mutations (e.g., M146V) |
| APOE | Late-onset Alzheimer's disease risk | APOE4 knock-in mice; human iPSC-derived neurons |
| BACE1 | Alzheimer's disease (therapeutic target) | BACE1 knockout mice; CRISPR KO in cell lines |
| CLU | Alzheimer's disease risk | CLU knockout mice; overexpression models |
Alzheimer's Disease
Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized by progressive cognitive decline. The amyloid cascade hypothesis posits that accumulation of amyloid-beta peptides, particularly Abeta42, initiates a pathogenic cascade leading to tau hyperphosphorylation, neuroinflammation, and neuronal loss. Genetic evidence from familial AD cases with mutations in APP, PSEN1, and PSEN2 strongly supports the causal role of amyloid-beta metabolism in AD. Soluble amyloid-beta oligomers are synaptotoxic and correlate with cognitive impairment. Current therapeutic strategies aim to reduce amyloid-beta production (e.g., BACE1 inhibitors) or enhance clearance (e.g., anti-amyloid antibodies).
Cerebral Amyloid Angiopathy
Cerebral amyloid angiopathy (CAA) is characterized by amyloid-beta deposition in the walls of cerebral blood vessels, leading to vessel fragility and hemorrhagic stroke. CAA is common in AD and may result from impaired clearance of amyloid-beta along perivascular drainage pathways. Mutations in APP, particularly those affecting the Abeta40/42 ratio, are associated with hereditary CAA. Understanding amyloid-beta metabolism in the vasculature is crucial for developing therapies for CAA.
Other Neurodegenerative Conditions
Amyloid-beta metabolism has been implicated in other neurodegenerative conditions, including Down syndrome (trisomy 21), where APP overexpression leads to early amyloid-beta deposition and AD-like pathology. Additionally, amyloid-beta may interact with other amyloidogenic proteins, such as tau and alpha-synuclein, contributing to overlapping pathologies. The role of amyloid-beta in traumatic brain injury and chronic traumatic encephalopathy is also an area of active research.
From amyloid-beta metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of BACE1 reduce amyloid-beta production? | BACE1 knockout cell lines (e.g., HEK293, SH-SY5Y) or mice |
| Does a specific APP mutation increase Abeta42/40 ratio? | Knock-in of APP mutations (e.g., Swedish, London) in cell lines or mice |
| Can a candidate gene regulate amyloid-beta clearance? | Overexpression or knockout of candidate gene in microglia or astrocytes |
| What is the effect of APOE isoforms on amyloid-beta aggregation? | APOE2/3/4 knock-in mice or human iPSC-derived neurons |
| Does a drug affect gamma-secretase activity? | Point mutations in PSEN1 to modulate enzyme activity |
| Can CRISPR screen identify novel modifiers of amyloid-beta toxicity? | Genome-wide CRISPR knockout library in cell models |
How to Study the amyloid-beta metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | Abeta40 and Abeta42 concentrations | Quantify amyloid-beta production in cell media or brain extracts |
| Thioflavin T fluorescence | Amyloid fibril formation | Monitor aggregation kinetics in vitro |
| PET imaging | Amyloid plaque burden in vivo | Diagnosis and clinical trials in AD |
| CRISPR knockout screen | Genes affecting amyloid-beta levels | Identify novel regulators of amyloid-beta metabolism |
| Co-immunoprecipitation | Protein-protein interactions | Map gamma-secretase complex components |
| Mass spectrometry | Amyloid-beta species and modifications | Characterize post-translational modifications |
| Western blot | APP processing fragments (C99, C83) | Assess secretase activity |
| Immunohistochemistry | Amyloid plaques in tissue | Evaluate pathology in mouse models |
Biochemical Assays for Amyloid-beta Production
Amyloid-beta levels can be measured using enzyme-linked immunosorbent assay (ELISA) specific for Abeta40 and Abeta42 in conditioned media from cell cultures or in brain tissue extracts. Immunoprecipitation followed by mass spectrometry can identify amyloid-beta species and post-translational modifications. These methods are essential for quantifying the effects of genetic manipulations or drug treatments on amyloid-beta metabolism.
Imaging Amyloid-beta Aggregation and Plaques
Thioflavin T and Congo red staining are used to detect amyloid fibrils in vitro and in tissue sections. In vivo, positron emission tomography (PET) with amyloid-binding tracers (e.g., Pittsburgh compound B) allows non-invasive visualization of amyloid plaques in animal models and humans. Fluorescence microscopy with conformation-specific antibodies can detect oligomers.
Genetic and CRISPR Screens
CRISPR-Cas9 knockout screens enable unbiased identification of genes that regulate amyloid-beta production or toxicity. For example, a genome-wide screen in APP-expressing cells can identify modifiers of Abeta42 levels. Similarly, CRISPR activation (CRISPRa) or interference (CRISPRi) can modulate gene expression to study dose-dependent effects. These approaches are powerful for discovering novel therapeutic targets.
Proteomics and Interactomics
Mass spectrometry-based proteomics can identify proteins interacting with APP or amyloid-beta, revealing components of the metabolic process. Co-immunoprecipitation coupled with mass spectrometry can map the gamma-secretase complex and its regulators. These methods provide a systems-level view of amyloid-beta metabolism.
How CRISPR Can Be Used to Study GO:0050435 amyloid-beta metabolic process
Knockout
CRISPR-Cas9 knockout of genes involved in amyloid-beta metabolism, such as BACE1 or PSEN1, can abolish or reduce amyloid-beta production, providing causal evidence for their roles. Knockout cell lines (e.g., HEK293, SH-SY5Y) are valuable for studying APP processing and for drug screening. However, complete knockout of essential genes like PSEN1 may be lethal, requiring inducible systems.
Point Mutation
Introducing disease-associated point mutations (e.g., APP Swedish KM670/671NL, PSEN1 M146V) using CRISPR base editing or homology-directed repair (HDR) allows precise modeling of familial AD. These models recapitulate altered amyloid-beta production and aggregation, enabling mechanistic studies and drug testing.
Knock-in
Knock-in of human APP or APOE isoforms into mouse models or cell lines via CRISPR can humanize the amyloid-beta metabolic process for translational research. For example, APOE4 knock-in mice develop amyloid pathology and cognitive deficits, serving as models for late-onset AD. Knock-in of tagged APP (e.g., HA or GFP) enables tracking of APP processing and localization.
Overexpression
CRISPR activation (CRISPRa) or traditional overexpression constructs can increase expression of APP or secretases to enhance amyloid-beta production, useful for studying aggregation and toxicity. Overexpression of mutant APP in transgenic mice (e.g., Tg2576) has been a cornerstone of AD research, though CRISPR-based overexpression offers more precise control.
How EDITGENE Supports amyloid-beta metabolic process Research
Researchers studying amyloid-beta metabolic process-related genes often need to determine whether a candidate gene is causally involved in amyloid-beta production, aggregation, or clearance. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional studies and drug discovery.
Contact EDITGENE today to design your custom CRISPR model for amyloid-beta metabolic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| BACE2 Knockout HEK293 Cell Line | EDJ-KQ2355 | Human | 25825 | Details Get a Quote |
| APEH Knockout HEK293 Cell Line | EDJ-KQ4068 | Human | 327 | Details Get a Quote |
| ACE Knockout HEK293 Cell Line | EDJ-KQ4427 | Human | 1636 | Details Get a Quote |
| IDE Knockout HEK293 Cell Line | EDJ-KQ4962 | Human | 3416 | Details Get a Quote |
| MGAT3 Knockout HEK293 Cell Line | EDJ-KQ5207 | Human | 4248 | Details Get a Quote |
| BACE1 Knockout HEK293 Cell Line | EDJ-KQ17788 | Human | 23621 | Details Get a Quote |
| MME Knockout HEK293 Cell Line | EDJ-KQ17789 | Human | 4311 | Details Get a Quote |
| ACE Knockout HCT 116 Cell Line | EDJ-KQ26969 | Human | 1636 | Details Get a Quote |
| BACE1 Knockout A-549 Cell Line | EDJ-KQ19872 | Human | 23621 | Details Get a Quote |
| BACE1 Knockout HCT 116 Cell Line | EDJ-KQ19873 | Human | 23621 | Details Get a Quote |
| BACE1 Knockout HeLa Cell Line | EDJ-KQ19874 | Human | 23621 | Details Get a Quote |
| BACE2 Knockout HCT 116 Cell Line | EDJ-KQ21465 | Human | 25825 | Details Get a Quote |
| BACE2 Knockout A-549 Cell Line | EDJ-KQ22787 | Human | 25825 | Details Get a Quote |
| BACE2 Knockout HeLa Cell Line | EDJ-KQ22789 | Human | 25825 | Details Get a Quote |
| APEH Knockout A-549 Cell Line | EDJ-KQ26438 | Human | 327 | Details Get a Quote |
Displaying Records 1 To 15 Of 31 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About amyloid-beta metabolic process
What is GO:0050435?
GO:0050435 is the Gene Ontology term for amyloid-beta metabolic process, defined as the chemical reactions and pathways involving amyloid-beta and its precursor, amyloid precursor protein (APP).
What genes are involved in amyloid-beta metabolic process?
Key genes include APP, BACE1, PSEN1, PSEN2, NCSTN, APH1A, APH1B, PEN2, APOE, LRP1, RAGE, IDE, MME, CLU, CR1, PICALM, and BIN1.
How is amyloid-beta produced?
Amyloid-beta is produced by sequential cleavage of APP by beta-secretase (BACE1) and gamma-secretase, releasing peptides of varying lengths, mainly Abeta40 and Abeta42.
What is the role of amyloid-beta in Alzheimer's disease?
Amyloid-beta, especially soluble oligomers, is thought to initiate a pathogenic cascade leading to synaptic dysfunction, tau pathology, and neurodegeneration in Alzheimer's disease.
What are the toxic forms of amyloid-beta?
Soluble oligomers are considered the most toxic forms, as they impair synaptic plasticity and correlate with cognitive decline.
How is amyloid-beta cleared from the brain?
Amyloid-beta is cleared by enzymatic degradation (e.g., neprilysin, IDE), receptor-mediated transport (LRP1, RAGE), and microglial phagocytosis.
What is the amyloid cascade hypothesis?
The amyloid cascade hypothesis proposes that accumulation of amyloid-beta is the primary event that triggers a cascade of tau hyperphosphorylation, neuroinflammation, and neuronal loss in Alzheimer's disease.
How do metals affect amyloid-beta?
Copper and zinc bind amyloid-beta, modulating its aggregation and toxicity; copper can promote oxidative stress.
What CRISPR models are used to study amyloid-beta metabolism?
Knockout, point mutation, knock-in, and overexpression models in cell lines and mice are used to dissect gene function and model disease mutations.
What methods measure amyloid-beta levels?
ELISA, mass spectrometry, Thioflavin T fluorescence, PET imaging, and Western blot are commonly used to quantify amyloid-beta production and aggregation.
Conclusion
The amyloid-beta metabolic process (GO:0050435) is a central pathway in Alzheimer's disease pathogenesis, encompassing APP processing, amyloid-beta aggregation, and clearance. Genetic and biochemical evidence strongly supports the amyloid cascade hypothesis, making this process a prime target for therapeutic intervention. Advances in CRISPR-based models and screening technologies are accelerating the discovery of novel regulators and drug candidates. EDITGENE's comprehensive services empower researchers to dissect this pathway with precision and translate findings into clinical applications.
References
- 1. Querfurth HW et al.. 2010. Alzheimer's disease.. N Engl J Med 362(4):329-44 PMID: 20107219
- 2. De-Paula VJ et al.. 2012. Alzheimer's disease.. Subcell Biochem 65:329-52 PMID: 23225010
- 3. Paroni G et al.. 2019. Understanding the Amyloid Hypothesis in Alzheimer's Disease.. J Alzheimers Dis 68(2):493-510 PMID: 30883346
- 4. Kayed R et al.. 2003. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.. Science 300(5618):486-9 PMID: 12702875
- 5. Nam E et al.. 2020. Synaptic Copper, Amyloid-β, and Neurotransmitters in Alzheimer's Disease.. Biochemistry 59(1):15-17 PMID: 31603659
- 8. Luft FC. 2003. Thinking about zinc.. J Mol Med (Berl) 81(10):597-9 PMID: 14628791
